Quantumzyme Corp. Achieves Current Information Status with OTC Markets Following Improved Disclosure Practices

Quantumzyme Corp. (OTC: QTZM), a biotechnology firm specializing in computational enzyme engineering, announced the removal of the 'Caveat Emptor' designation by OTC Markets Group. This change reclassifies Quantumzyme as a Current Information issuer with a Verified Profile, indicating compliance with the OTCID disclosure framework. The removal follows the company's adoption of improved disclosure practices, including updated financial reports and corporate transparency measures, alongside the retention of securities counsel to ensure regulatory adherence.

The significance of this development lies in its implications for market perception and investor confidence. The 'Caveat Emptor' label, which translates to 'buyer beware,' is applied by OTC Markets to alert investors to potential public information concerns or regulatory issues with a company. Its removal signals that Quantumzyme has addressed these concerns to the satisfaction of the marketplace operator. Achieving Current Information status is a critical milestone for companies trading on the over-the-counter markets, as it demonstrates a commitment to transparency and regulatory compliance. This reclassification potentially broadens the company's investor base, as some institutional investors and funds have policies restricting investments in companies with such warnings.

Naveen Kulkarni, CEO of Quantumzyme, emphasized the company's commitment to transparency and market integrity, stating the lifting of the warning allows a refocus on business strategy and shareholder value. This statement underscores the operational burden such designations can impose, often requiring management to divert resources from core business activities to address compliance issues. The shift to a Verified Profile status within the OTC Markets framework provides a more structured and vetted platform for presenting corporate information to the public.

Quantumzyme also addressed past unauthorized promotional activities, reiterating its non-involvement and condemnation of such actions, and highlighted its cooperation with related inquiries. This proactive communication is part of the broader transparency measures cited as contributing to the designation's removal. For stakeholders seeking detailed information, the company directs attention to its official online resources. Further corporate details and disclosures are available through the company's website and its profile on the OTC Markets platform. The move from Caveat Emptor to Current Information status represents a substantive step in corporate governance for Quantumzyme, potentially reducing perceived investment risk and aligning the company with higher standards of market practice.